HOME >> MEDICINE >> NEWS
Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence

published in the Journal of Clinical Oncology, included among its treatment options for women initially started on tamoxifen a switch to an aromatase inhibitor based on data from the AROMASIN study, IES.

Professor Charles Coombes, Director of the Cancer Research UK Laboratories at Imperial College London, Hammersmith and Charing Cross Hospitals presented an update from the IES today at the 27th Annual San Antonio Breast Cancer Symposium based on 37.4 months of median follow-up and 4,740 patients. These findings showed that 193 women treated with exemestane experienced a local or distant recurrence of disease compared with 264 women who continued on tamoxifen. A 30 percent reduction in risk of recurrence in breast cancer was reported when women were switched to AROMASIN after 2-3 years of tamoxifen, compared to those who continued on tamoxifen for a total of 5 years, the current standard of care (P=0.00005). In addition 54 percent fewer cases of contralateral breast cancer (12 vs. 26) developed in women treated with AROMASIN compared to those who remained on tamoxifen (P=0.04).

Breast cancer is the second leading cause of cancer death among women. It is estimated that 213,910 women in the United States will be diagnosed with breast cancer in 2004 and more than 40,921 women will lose their lives to the disease. Breast cancer is estrogen-dependent in 2/3 of all cases.

AROMASIN (exemestane) was approved in the United States late in 1999 for the treatment of advanced breast cancer in postmenopausal women whose tumors have stopped responding to tamoxifen. It also is approved for use in Europe, Japan, and South America.

Unlike other aromatase inhibitors, exemestane is a steroidal aromatase inactivator, which means it selectively targets and irreversibly binds to the aromatase enzyme, which is required to produce estrogen. Without estrogen, breast cancer cells cannot survive.

Exemestane is well tolerated and the side effects ass
'"/>

Contact: Steven Cooper
steven.cooper@edelman.com
917-301-7566
Edelman Public Relations
8-Dec-2004


Page: 1 2 3

Related medicine news :

1. Updated press release to October 2004 Cochrane Review
2. Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
6. Neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds
7. Different methods of adjuvant chemotherapy for colorectal cancer have similar outcomes
8. Study supports tailoring adjuvant therapy for early-stage breast cancer
9. Nordic collaboration gives new insights into adjuvant chemotherapy
10. New tipifarnib (R115777) data in AML presented at American Society of Hematology Annual Meeting
11. Elderly cancer patients are significantly under-represented in cancer clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang ... persons with autism and other developmental disabilities, as well as supporting staff in ... adolescents with autism, school consultation, and staff development. She joined the company in ...
(Date:8/29/2020)... ... 29, 2020 , ... When professor and author Randy Pausch was diagnosed with ... would. Rather than become melancholic, however, he put together a final lecture in Carnegie ... Pausch took a negative situation and turned it into something that inspired millions of ...
(Date:8/28/2020)... ... August 28, 2020 , ... WHAT ... help treat patients with respiratory conditions, including COVID-19, while reducing the need for ... but it captures exhaled gas and scrubs it free of carbon dioxide in ...
(Date:8/28/2020)... ... August 28, 2020 , ... With in-person gluten-free events ... continue helping the specialty-diet community connect with great, gluten-free brands. At the ... giveaways, chat with brands & watch over 50 educational classes... all online from ...
(Date:8/28/2020)... , ... August 28, 2020 , ... ... in advising Adventist Health on its investment in Synchronous Health, a tech-enabled behavioral ... that combines the strength of human empathy with artificial intelligence (AI) to increase ...
Breaking Medicine News(10 mins):
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... research and advisory guide, has named Cloudticity a Gold winner in the 15th ... industry and peer recogniti o ns from Network Products Guide honoring ...
(Date:8/28/2020)... ... August 28, 2020 , ... Dr. Mark Surrey ... endoscopic surgeon and serves as a clinical professor in the Department of OBGYN at ... American Laparoscopy Society & Pacific Coast Reproductive Society and is a Clinical Director of ...
(Date:8/27/2020)... ... August 27, 2020 , ... InfoMC, a leading provider ... of their 2020 System and Organizational Controls (SOC) 1® Type 2 and SOC ... compliance assessment. These achievements reflect their long-standing commitment to privacy, security, and risk ...
Breaking Medicine Technology:
Cached News: